BioVie, Inc. (BIVI) Dividend History

BioVie, Inc. is a biotech company focused on developing innovative therapies for neurodegenerative and liver diseases. The company is known for its research into drug candidates aimed at addressing unmet medical needs, particularly in conditions such as hepatic encephalopathy. BioVie's approach involves leveraging novel mechanisms and proprietary formulations to create impactful treatments.

680 W Nye Lane, Carson City, NV, 89703
Phone: 775-888-3162
Website: https://www.bioviepharma.com

Dividend History

BioVie, Inc. currently does not pay dividends

Company News

BIOVIE ALERT: Bragar Eagel & Squire, P.C. is Investigating BioVie Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C. is investigating potential claims against BioVie Inc. on behalf of long-term stockholders following a class action complaint alleging the company made materially false and/or misleading statements about its business, operations, and prospects.

GlobeNewswire Inc.
BioVie Initiates SUNRISE-PD Clinical Trial Assessing Bezisterim in Early Parkinson’s Disease with First Patient Enrolled

BioVie has initiated the SUNRISE-PD clinical trial to evaluate the safety and efficacy of its drug candidate bezisterim in patients with early-stage Parkinson's disease. The trial will incorporate a decentralized approach to allow for remote participation, and is supported by leading Parkinson's foundations.

GlobeNewswire Inc.
BioVie Inc. Announces Pricing of Public Offering

BioVie Inc. (NASDAQ: BIVI) announced the pricing of a $3 million public offering of 1,960,800 shares of its common stock and associated warrants. The company plans to use the net proceeds for working capital and general corporate purposes.

GlobeNewswire Inc.
BioVie Announces FDA Authorization of Investigational New Drug Application for Phase 2 Trial to Evaluate Bezisterim in Long COVID

BioVie received FDA authorization to evaluate its drug bezisterim in a Phase 2 trial for treating neurological symptoms associated with long COVID. The trial is supported by a $12.6 million grant from the U.S. Department of Defense.

GlobeNewswire Inc.
BioVie Announces Clinical Data Showing Epigenetic Basis for How Bezisterim May Modulate Inflammation and the Biological Aging Process at the 11th Aging Research and Drug Discovery Meeting

BioVie presented clinical data showing that its drug candidate bezisterim may have the ability to modulate DNA methylation, reduce inflammation, and impact the biological aging process. The data suggests bezisterim could have potential in treating various neurodegenerative disorders.

GlobeNewswire Inc.

Dividend data last updated 06/07/2025 10:15:28 UTC